Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Reproductive Sciences
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lea, J. S.
Right arrow Articles by Muller, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lea, J. S.
Right arrow Articles by Sunaga, N.
Right arrow Articles by Sato, M.
Right arrow Articles by Kalahasti, G.
Right arrow Articles by Miller, D. S.
Right arrow Articles by Minna, J. D.
Right arrow Articles by Muller, C. Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells

Jayanthi S. Lea, MD

J7. 124, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032; Hamon Center of Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, and University of New Mexico Health Sciences Center, Albuquerque; jayanthi.lea{at}utsouthwestern.edu

Noriaki Sunaga, MD

Mitsuo Sato, MD

Geetha Kalahasti, MS

David S. Miller, MD

John D. Minna, MD

Carolyn Y. Muller, MD

Hamon Center of Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, and University of New Mexico Health Sciences Center, Albuquerque

Silencing the expression of human papillomavirus (HPV) oncoproteins should have therapeutic benefits for cervical cancer. The authors' objective was to study RNA interference of the HPV 18 E6/E7 bicistronic mRNA with E6 small interfering RNA (siRNA) and E7 siRNA and determine the effect of each siRNA on oncoprotein expression, resultant cell growth, and downstream molecular effects. RNA interference was used to knockdown HPV 18 E6 and E7 oncoproteins on the HPV 18 positive cervical cancer cell lines HeLa and C4I. Western blotting was used to assay for each oncoprotein expression and select downstream molecular targets. Cell cycle analyses, cell viability assays, and colony formation assays were performed to determine the effect of treatment by both HPV 18 E6 siRNA and E7 siRNA. The transfection reagent oligofectamine and Tax siRNA were used as negative controls. Transfection with E6 siRNA caused complete loss of E6 but not E7 oncoprotein. However, E7 siRNA induced complete loss of both E6 and E7 oncoproteins. E6 siRNA mediated the reexpression of p53 protein and a moderate decrease in phosphorylated retinoblastoma protein expression (pRb), resulting in decreased colony formation. Transfection with E7 siRNA mediated a robust increase in p53 expression and complete loss of pRb, resulting in a marked decrease in colony formation compared to the E6 siRNA (P =.001). Flow cytometry revealed significantly increased apoptotic cells with E7 siRNA compared to E6 siRNA and control. RNA interference targeting the E7 portion of the bicistronic HPV 18 mRNA can silence both E6 and E7 oncoproteins and is most effective in cervical cancer growth inhibition.

Key Words: Cervical cancer • HPV • RNA interference • targeted therapy

Reproductive Sciences, Vol. 14, No. 1, 20-28 (2007)
DOI: 10.1177/1933719106298189
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. V. Hoekstra, E. C. Sefton, E. Berry, Z. Lu, J. Hardt, E. Marsh, P. Yin, J. Clardy, D. Chakravarti, S. Bulun, et al.
Progestins Activate the AKT Pathway in Leiomyoma Cells and Promote Survival
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1768 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Wilkens, K. Chwalisz, C. Han, J. Walker, I. T. Cameron, S. Ingamells, A. C. Lawrence, M. A. Lumsden, D. Hapangama, A. R. W. Williams, et al.
Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy
J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4664 - 4671.
[Abstract] [Full Text] [PDF]